2016年上半年美国FDA批准的新分子实体与评价:癌症、罕见病治疗用药和抗病毒药物被引量：2

Updates of New Molecular Entities Approved by the FDA in the First-Half of 2016:Cancer,Rare Disease and Anti-Viral Medications

下载PDF

导出

摘要 2016年上半年,FDA批准了14个新分子实体和新生物制品。本文将介绍和评价癌症、罕见病治疗用药和抗病毒药物。 The US FDA approved 14 new molecular entities and new therapeutic biological products in the first-half of 2016. This article provides an update and evaluation of the new drugs approved for the treatment of cancer, rare diseases, and anti-viral medications.

作者孙树森赵志刚

机构地区美国西新英格兰大学药学院首都医科大学附属北京天坛医院药学部

出处《药品评价》 CAS 2016年第16期7-12,25,共7页 Drug Evaluation

基金 "药物管理平台"子课题国家科技部"脑血管病创新药物临床评价技术平台"重大专项基金编号:2008ZX09312-00

关键词 FDA 新分子实体癌症罕见病抗病毒 FDA New Molecular Entity Cancer Rare Disease Anti-viral

分类号 R954 [医药卫生—药学]

引文网络
相关文献

参考文献4

1孙树森,韩容,赵志刚.2015年上半年美国FDA批准的新分子实体与评价:消化系统疾病、皮肤病、感染和罕见病治疗用药[J].药品评价,2015,12(14):5-10. 被引量：11
2孙树森,赵志刚.2015年下半年美国FDA批准的新分子实体与评价:心血管和精神系统疾病、抗病毒感染、女性性欲低下障碍、糖尿病治疗用药和化疗止吐药[J].药品评价,2016,13(2):20-28. 被引量：3
3孙树森,李新辰,韩容,赵志刚.2014年美国FDA批准的新分子实体与评价:感染和传染病治疗用药[J].药品评价,2015,12(2):8-14. 被引量：6
4Aldo Bonaventura,Fabrizio Montecucco.Sofosbuvir/velpatasvir: A promising combination[J].World Journal of Hepatology,2016,8(19):785-789. 被引量：2

二级参考文献68

1BoucherHW, WilcoxM, TalbotGH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection[J]. N Engl J Med,2014, 370(23):2169-2179.
2Wilcox M, Boucher HW, Talbot GH, et al. Discover 2: a randomized, double-blind study of dalbavancin(DAL) compared to vancomycin(V)(with an option to switch to linezolid(L)) in treatment of acute bacterial skin and skin structure infections(ABSSI) [Abstract]. Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013.
3Denver, CO. Abstrct L-202. Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections[J]. N Engl J Med, 2014, 370(23):2180-2190.
4Corey R, Perez A, Moeck G, et al. A single-dose of oritavancin(ORI) is comparable to 7-10 days of vancomycin(VAN) in the treatment of acute bacterial skin and skin structure infections(ABSSSI): the SOLO ii study [abstract no. L-206c]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 Sep 2013; Denver, Colorado.
5Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial[J]. JAMA, 2013, 309(6):559-569.
6Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections(ESTABLiSH-2): a randomized, double-blind, phase 3, non-inferiority trial[J]. Lancet Infect Dis, 2014, 14(8):696-705.
7Drugs for MRSA skin and soft-tissue infections[J]. Med Lett Drugs Ther, 2014, 59:147.
8Rybak JM, Marx K, Martin CA. Early experience with tezolid: clinical efficacy, pharmacodynamics, and resistance[J]. Pharmacotherapy, 2014, 34(11): 1198-1208.
9Label of Ceftolozane/tazobactam. FDA website.http://www. acce ssdata.fda.gov/drugsat fda_docs/label/2014/2068291bl.pdf2 2014-12-19/2014-12-22.
10Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections[J]. Expert OpinPharmacother, 2015, I6(2):271-280.